Home > Neurology > EAN 2022 > COVID-19 > EAN 2022 Highlights Podcast

EAN 2022 Highlights Podcast

Presented by
Robert van den Heuvel, Medicom
EAN 2022

In this episode (17:23), Medicom’s correspondent covers 6 presentations from the European Academy of Neurology (EAN) congress, held virtually and in-person from 25-28 June 2022.

The topics discussed are:

  1. COVID-19 elevates risk of neurodegenerative disorders
    COVID-19 positive outpatients have an increased risk of a broad range of neurodegenerative and cerebrovascular disorders compared with participants who tested negative. However, no excess risk was detected compared with influenza A/B and community-acquired pneumonia, except for ischaemic stroke.
  2. Teriflunomide in children with MS: final results of TERIKIDS
    The final results of the open-label extension (OLE) period of the TERIKIDS study showed that continuous teriflunomide numerically – but not significantly – lowered the relapse risk and disability progression compared with delayed teriflunomide initiation in paediatric multiple sclerosis (MS) patients. MRI lesion count was significantly reduced and the safety profile was manageable. The beneficial effects of teriflunomide in TERIKIDS are similar to those seen in adults.
  3. Sleep disorder associated with short-term risk of dementia
    Results of a Danish study suggest that the diagnosis of a sleep disorder is significantly associated with the short-term risk of dementia. This could imply that sleep disorders are an early symptom of dementia, a risk factor for dementia, or both.
  4. Long-term effects of avalglucosidase alfa in late-onset Pompe disease
    Patients with late-onset Pompe disease treated with avalglucosidase alfa (AVAL) for 97 weeks maintained improvement from baseline in respiratory function, motor function, muscle strength, and health-related quality-of-life in the extended treatment period of the COMET trial. Participants who switched to AVAL after 49 weeks of treatment with alglucosidase alfa (ALGLU) showed stabilisation of treatment effect.
  5. Over a third of patients respons late to CGRP antibodies
    Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies (mAbs) elicited a late response in over one-third of migraine patients who were considered non-responders at 12 weeks, in a real-life study with 912 participants. The authors therefore advocated to extend the efficacy evaluation of CGRP mAbs to 6 months.
  6. Seizure forecasting with non- and minimally-invasive devices
    An international project has managed to establish the feasibility of ambulatory seizure forecasting with multiple minimally-invasive devices, from medical-grade/research-grade devices to fitness trackers, using seizure cycles and subcutaneous EEG. Epileptic seizure cycles are common, measurable with different modalities, and strong predictors of future seizures.

Enjoy listening!

Copyright ©2022 Medicom Medical Publishers



Posted on